Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on July 28, 2025.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma reported its Q1 FY2026 results with consolidated revenue from operations of Rs. 1,303 cr, up 14% YoY from Rs. 1,145 cr. EBITDA rose 6% to Rs. 351 cr (margin 27%), while profit after tax grew 4% to Rs. 255 cr (margin 20%). The company highlighted a Rs. 25 cr mark-to-market forex loss during the quarter; excluding this one-time hit, EBITDA would have been Rs. 376 cr (margin 29%) and PAT would have grown 12% (margin 21%). By segment, US Generics surged 36% to Rs. 310 cr and India Branded Generics grew 16% to Rs. 409 cr, while Africa Branded was flat and Africa Institution declined 8%. Cash flow from operations was healthy at Rs. 282 cr with ROCE at 33% and RONW at 26%. Statutory auditor B S R & Co. LLP issued an unmodified limited review opinion on both standalone and consolidated results.
Strong, broad-based revenue growth across India and US businesses reinforces the company's growth trajectory. Reported EBITDA margin compression is largely driven by a one-time forex MTM loss; underlying core margins remain stable, which should reassure investors looking past the headline optics.